4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮 CAS#: 1038620-68-6

4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮

生物活性体外研究体内研究用途与合成方法 MSDS 4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮价格(试剂级) 上下游产品信息

中文名称	4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮
中文同义词	4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮
英文名称	Purfalcamine
英文同义词	Purfalcamine;Methanone, [4-[[2-[(trans-4-aminocyclohexyl)amino]-9-(3-fluorophenyl)-9H-purin-6-yl]amino]phenyl]-1-piperidinyl-
CAS号	1038620-68-6
分子式	C29H33FN8O
分子量	528.62
EINECS号
相关类别
Mol文件	1038620-68-6.mol
结构式

4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮性质

沸点	784.8±70.0 °C(Predicted)
密度	1.42±0.1 g/cm3(Predicted)
储存条件	Store at -20°C
形态	固体
酸度系数(pKa)	10.41±0.70(Predicted)
颜色	白色至米白色

4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮用途与合成方法

生物活性

Purfalcamine 是一种具有口服活性，选择性的恶性疟原虫钙依赖性蛋白激酶 1 (PfCDPK1) 抑制剂，IC50 为 17 nM，EC50 为 230 nM。Purfalcamine 具有抗疟疾活性，可以引起疟原虫在裂殖体阶段的发育停滞。

体外研究

Purfalcamine has low activity against Toxoplasma gondii calcium-dependent protein kinase 3 (TgCDPK3).
Purfalcamine (225, 450 nM) has no effect on the parasitemia in the first 32 hours. After about 40 hours, parasite level remains stable and then begins dropping.
Purfalcamine inhibits proliferation with EC ₅₀ s of 171-259 nM for P. falciparum strains (3D7, Dd2, FCB, HB3 and W2), which indicates effectiveness against drug-resistant parasites.
Given that the EC ₅₀ value for P. falciparum (3D7) is 230 nM, Purfalcamine shows a therapeutic window ranging from 23-fold to 36-fold (EC ₅₀ s for CHO=12.33 μM, HEp2=7.235 μM, HeLa=7.029 μM and Huh7=5.476 μM).

体内研究

Purfalcamine (10 mg/kg; oral gavage; BID; for 6 days) demonstrates a delay in the onset of parasitemia in treated mice.
Purfalcamine (20 mg/kg; orally gavage) exhibits a C _max of 2.6 μM with a half-life of 3.1 hours.

Animal Model:	Male BALB/c mice, 7 weeks of age with the malaria parasite
Dosage:	10 mg/kg
Administration:	Oral gavage; BID; for 6 days
Result:	Demonstrated a delay in the onset of parasitemia in treated mice when compared with control mice.

Animal Model:	Five- to six-week-old male Balb/c mice (22-25 g)
Dosage:	20 mg/kg (Pharmacokinetic Analysis)
Administration:	Orally gavage
Result:	Exhibited a maximum plasma exposure (C _max ) of 2.6 μM with a half-life of 3.1 hours.

安全信息

MSDS信息

4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮价格(试剂级)

更新日期	产品编号	产品名称	CAS号	包装	价格
2026/09/15	HY-117015	4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮 Purfalcamine	1038620-68-6	1 mg	1800元
2026/09/15	HY-117015	4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮 Purfalcamine	1038620-68-6	5mg	4500元

4-[[2-[(反式-4-氨基环己基)氨基]-9-(3-氟苯基)-9H-嘌呤-6-基]氨基]苯基]-1-哌啶基甲酮